« Back to News

Press Releases

March 1, 2024

ROME Therapeutics today announced that members of the ROME Senior Leadership Team will participate in the TD Cowen 44th Annual Health Care Conference.

January 4, 2024

ROME Therapeutics Appoints Heike Keilhack, Ph.D., as Chief Scientific Officer

December 14, 2023

ROME Publishes Landmark Nature Paper Revealing First High-Resolution Structure of LINE-1 Reverse Transcriptase (RT) for Drug Discovery

November 16, 2023

ROME Therapeutics Presents First Data to Validate LINE-1 RT as a Novel Target in Autoimmune Diseases and the Therapeutic Potential of its First-in-Class LINE-1 RT Inhibitors

November 1, 2023

Enara Bio, ROME Therapeutics and Nucleome Therapeutics to Host 2nd Annual Dark Genome Symposium

October 4, 2023

ROME Expands Leadership Team with the Appointment of Industry Veteran Kyle Kuvalanka as Chief Financial Officer and Chief Business Officer

September 12, 2023

ROME Therapeutics Closes Oversubscribed $72 Million Series B Extension to Support Advancement of Lead Program into Clinical Development for Autoimmune Disease

March 9, 2023

ROME Therapeutics Appoints Keith Wilcoxen, Ph.D., as Executive Vice President, Early Development

November 10, 2022

ROME Therapeutics Demonstrates Efficacy of its Novel LINE-1 Reverse Transcriptase Inhibitor in Translational Models of Autoimmune Disease

November 2, 2022

ROME Therapeutics and Enara Bio to Host Inaugural Dark Genome Symposium Convening Industry and Academic Leaders to Catalyze Therapeutic Application of Dark Genome Research

July 18, 2022

ROME Therapeutics Appoints Industry Veteran Jeff Hatfield as Chair of Board of Directors

June 30, 2022

ROME Therapeutics Announces Publication of First Crystal Structure of a Human Endogenous Reverse Transcriptase in PNAS

April 26, 2022

ROME Therapeutics Appoints Nurjana Bachman, Ph.D., as Senior Vice President, Corporate Development and Strategy

November 8, 2021

ROME Therapeutics Announces Preclinical Data Demonstrating Inhibition of Endogenous Reverse Transcriptase Activity Blocks Immune Response in Autoimmune Disease Models

September 14, 2021

ROME Therapeutics Secures $77 Million in Series B Financing to Advance Repeatome-derived Pipeline for Cancer and Autoimmune Diseases and Expand Repeatomics Platform

July 19, 2021

ROME Therapeutics Expands Science Leadership in Oncology, Data Science and New Target Discovery

March 1, 2021

ROME Therapeutics announces the appointment of Scott Biller, Ph.D. to its board.

September 28, 2020

ROME Therapeutics announces that it has been named by Fierce Biotech as one of 2020’s Fierce 15 biotechnology companies

August 19, 2020

ROME Therapeutics Appoints Drug Discovery Veteran Dennis Zaller, Ph.D., as Chief Scientific Officer

April 27, 2020

ROME Therapeutics Launches to Develop Novel Therapies for Cancer and Autoimmune Diseases by Harnessing the Power of the Repeatome